Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996227 · ClinicalTrials.gov registry record · NA
Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine
A NA study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- NA
- Development phase
- 514
- Enrollment target
NCT02996227: Completed NA study, sponsored by The Cleveland Clinic.
NCT02996227 is a NA study that has completed, run by The Cleveland Clinic. The registered enrollment target is 514 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02996227, a NA study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 514 participants
- Enrollment target
Study Summary
Comparison of Bilateral Transversus Abdominis Plane Block with Exparel versus Continuous Epidural Analgesia With Bupivacaine
Primary Outcome
Pain scores will be measured using a Verbal Response Scale (VRS). VRS is a scale from 0 to 10 where 0 signifies no pain and 10 signifies the worst pain ever experienced. The VRS will be recorded every 4 hours for 72 hours after discharge from the PACU. Summary statistics of pain scores are reported as means ± standard deviations of average pain during the first 72 postoperative hours
Interventions
- DRUG Bupivacaine
- DRUG EXPAREL
- PROCEDURE TAP block
- PROCEDURE Epidural analgesia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 514 participants |
| Start Date | 2016-12 |
| Est. Completion | 2019-10 |
| Phase | NA |
What the finished NCT02996227 record still lists
NCT02996227 is an interventional study that assigns participants to a tested intervention. The registered 514 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 4 interventions - of which Bupivacaine is the first listed.
NCT02996227 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02996227 about?
NCT02996227 is a clinical study titled "Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine". Comparison of Bilateral Transversus Abdominis Plane Block with Exparel versus Continuous Epidural Analgesia With Bupivacaine
What is the current status of trial NCT02996227?
This trial is currently completed. It is a NA study. The enrollment target is 514 participants. The study started on 2016-12. Estimated completion is 2019-10.
What interventions are being tested in trial NCT02996227?
The interventions under investigation include: Bupivacaine (DRUG), EXPAREL (DRUG), TAP block (PROCEDURE), Epidural analgesia (PROCEDURE).
Who is sponsoring clinical trial NCT02996227?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02996227's enrollment target sits among peer trials
514 192nd of 2000 higher than 1,809 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
- NCT06585488 · 514 participants · Phase 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
- NCT06716606 · 514 participants · Phase 3
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- NCT05577819 · 515 participants · NA
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia